Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

ARQT

Arcutis Biotherapeutics Inc

Apr 29 • 04:00PM ET

8.78

Dollar change +0.31
Percentage change 3.66	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IBB IWO LABU DWAS SCHA PTH VTWO

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	15.40%	Shs Outstand	114.97M	Perf Week	-1.79%
Market Cap	1.01B	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-0.06%	Shs Float	97.27M	Perf Month	-11.40%
Income	-	PEG	-	EPS next Q	-0.69	Inst Own	84.54%	Short Float	20.21%	Perf Quarter	44.88%
Sales	-	P/S	-	EPS this Y	39.52%	Inst Trans	9.83%	Short Ratio	4.57	Perf Half Y	270.46%
Book/sh	0.92	P/B	9.58	EPS next Y	37.67%	ROA	-	Short Interest	19.66M	Perf Year	-36.19%
Cash/sh	2.37	P/C	3.70	EPS next 5Y	9.80%	ROE	-	52W Range	1.76 - 15.21	Perf YTD	171.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-48.07%	ROI	-	52W High	-42.27%	Beta	1.17
Dividend TTM	-	Quick Ratio	6.80	Sales past 5Y	303.42%	Gross Margin	-	52W Low	398.86%	ATR (14)	0.76
Dividend Ex-Date	-	Current Ratio	7.08	EPS Y/Y TTM	-35.85%	Oper. Margin	-8183.04%	RSI (14)	40.45	Volatility	5.69% 8.11%
Employees	296	Debt/Eq	2.32	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.33	Target Price	18.00
Option/Short	Yes / Yes	LT Debt/Eq	2.31	EPS Q/Q	62.05%	Payout	-	Rel Volume	0.49	Prev Close	8.47
Sales Surprise	18.56%	EPS Surprise	7.94%	Sales Q/Q	1765.66%	Earnings	Feb 27 BMO	Avg Volume	4.30M	Price	8.78
SMA20	-13.38%	SMA50	-13.27%	SMA200	35.10%	Trades		Volume	2,117,829	Change	3.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-03-24	Upgrade	Mizuho	Neutral → Buy	$4 → $8
Oct-26-23	Downgrade	Mizuho	Buy → Neutral	$57 → $4
Oct-13-23	Downgrade	Goldman	Buy → Neutral	$32 → $6
Sep-07-22	Initiated	Needham	Buy	$46
Mar-17-22	Initiated	Goldman	Buy	$45
Jun-30-21	Initiated	Mizuho	Buy	$58
May-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$52
Nov-09-20	Upgrade	Goldman	Neutral → Buy	$34 → $36
Oct-08-20	Initiated	Truist	Buy	$38
Feb-25-20	Initiated	Guggenheim	Buy	$36
Feb-25-20	Initiated	Goldman	Neutral	$30
Feb-25-20	Initiated	Cowen	Outperform	$55
Feb-25-20	Initiated	Cantor Fitzgerald	Overweight	$50

Show Previous Ratings

Apr-29-24 04:00PM	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 (GlobeNewswire)
Apr-10-24 08:00AM	Arcutis Appoints David Topper as Chief Financial Officer (GlobeNewswire)
Apr-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.49%
Apr-01-24 07:00AM	Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve Cream (GlobeNewswire)
Mar-28-24 08:00AM	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
09:55AM	Loading…
Mar-19-24 09:55AM	Arcutis Biotherapeutics, Inc. (ARQT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-18-24 09:55AM	Wall Street Analysts See a 54.78% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks)
Mar-11-24 08:00AM	Arcutis Promotes Todd Tucker to Chief Human Resources Officer (GlobeNewswire) -9.96%
Mar-10-24 04:00PM	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-09-24 04:00PM	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction (GlobeNewswire)
Mar-08-24 07:33PM	Peabody Energy, Citi Trends, and More Stocks See Action From Activist Investors (Barrons.com) +7.42%
Mar-05-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-24 04:00PM	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire) -6.97%
08:00AM	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting (GlobeNewswire)
Mar-01-24 09:55AM	Wall Street Analysts See a 58.85% Upside in Arcutis Biotherapeutics, Inc. (ARQT): Can the Stock Really Move This High? (Zacks) +14.49%
09:40AM	Loading…
09:40AM	Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-29-24 05:00PM	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
11:33AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 11:30PM	Arcutis Announces Pricing of $150 Million Public Offering (GlobeNewswire)
04:10PM	Arcutis Announces Proposed Public Offering (GlobeNewswire)
04:00PM	Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan (GlobeNewswire)
12:16AM	Q4 2023 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 08:11AM	Arcutis Biotherapeutics Inc (ARQT) Reports Significant Revenue Growth in Q4 2023 (GuruFocus.com) +9.70%
05:50AM	Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-24 08:00AM	Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) +16.69%
Feb-06-24 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.32%
Feb-01-24 03:04PM	Steven Cohen's Point72 Asset Management Acquires New Stake in Arcutis Biotherapeutics Inc (GuruFocus.com) +13.12%
Jan-31-24 08:00AM	Arcutis to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-29-24 08:00AM	Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial (GlobeNewswire) +14.34%
Jan-22-24 08:00AM	ZORYVE (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States (GlobeNewswire) +8.92%
12:00PM	Loading…
Jan-18-24 12:00PM	Arcutis Biotherapeutics, Inc. (ARQT) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
Jan-14-24 04:00AM	ZORYVE (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids (GlobeNewswire)
04:00AM	Majority of Individuals with Atopic Dermatitis Improved with Arcutis' Roflumilast Cream 0.15% According to New Data from Phase 3 Program (GlobeNewswire)
Dec-23-23 07:32PM	11 High Growth Micro-Cap Stocks to Buy (Insider Monkey)
Dec-19-23 11:48AM	Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis (Zacks)
Dec-18-23 06:02AM	Arcutis Biotherapeutics receives FDA approval for ZORYVE to treat seborrheic dermatitis (Pharmaceutical Business Review)
04:58AM	Arcutis shares jump after FDA approves drug for chronic skin condition (Investing.com)
Dec-15-23 05:19PM	UPDATE 3-US FDA approves Arcutis' drug to treat chronic skin disease (Reuters)
05:14PM	US FDA approves Arcutis' drug to treat chronic skin disease (Reuters)
05:11PM	FDA Approves Arcutis' ZORYVE (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older (GlobeNewswire)
Dec-01-23 10:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.15%
Nov-29-23 08:00AM	FDA Accepts Arcutis' Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6 (GlobeNewswire) -6.86%
Nov-17-23 09:35AM	After Plunging -35.64% in 4 Weeks, Here's Why the Trend Might Reverse for Arcutis Biotherapeutics, Inc. (ARQT) (Zacks)
Nov-16-23 11:04PM	Polar Capital Holdings Plc Bolsters Portfolio with Arcutis Biotherapeutics Inc Stake (GuruFocus.com) -6.25%
Nov-15-23 01:26PM	3 Biotech Stocks With Key Catalysts Coming in December (InvestorPlace)
Nov-14-23 05:04PM	FMR LLC Reduces Stake in Arcutis Biotherapeutics Inc (GuruFocus.com)
Nov-05-23 03:55PM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 09:47AM	Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2023 Earnings: Revenue Soars to $38.1 Million (GuruFocus.com) +9.91%
07:30AM	Arcutis Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-23 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-01-23 09:35AM	Down -50.77% in 4 Weeks, Here's Why You Should You Buy the Dip in Arcutis Biotherapeutics, Inc. (ARQT) (Zacks)
Oct-31-23 09:35AM	Arcutis Biotherapeutics, Inc. (ARQT) Loses -51.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Oct-26-23 12:32PM	Health Care Roundup: Market Talk (The Wall Street Journal)
Oct-25-23 04:00PM	Arcutis to Report Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-20-23 08:00AM	New Data Shows ZORYVE (Roflumilast) Cream 0.3% Provided Measurable Improvement of Plaque Psoriasis in Nearly All Individuals in DERMIS Trials (GlobeNewswire) -18.65%
Oct-19-23 11:45PM	Arcutis Announces Pricing of $100 Million Public Offering (GlobeNewswire) -6.19%
04:04PM	Arcutis Announces Proposed Public Offering (GlobeNewswire)
Oct-13-23 08:00AM	Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Oct-09-23 08:52AM	Arcutis (ARQT) Up on FDA Nod for Zoryve Label Expansion (Zacks)
Oct-06-23 08:00AM	FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11 (GlobeNewswire) +5.87%
Oct-05-23 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-27-23 08:00AM	Arcutis Appoints L. Todd Edwards as Chief Commercial Officer (GlobeNewswire)
04:16AM	Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last? (Zacks)
Sep-25-23 04:17PM	Mizuho reaffirms 'Buy' recommendation for Arcutis Biotherapeutics, amidst mixed institutional sentiment (Investing.com) +7.43%
09:00AM	New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis (GlobeNewswire)
Sep-19-23 07:30AM	Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
Sep-15-23 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-23 08:32AM	Arcutis (ARQT) Files sNDA for Zoryve in Atopic Dermatitis, Stock Up (Zacks) -8.42%
Sep-12-23 07:30AM	Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older (GlobeNewswire) +5.13%
Sep-07-23 03:08PM	Why Shares of Arcutis Biotherapeutics Fell This Week (Motley Fool)
08:15AM	Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD) (GlobeNewswire)
Sep-05-23 04:00PM	Arcutis to Present at Upcoming Investor Conference (GlobeNewswire) -7.59%
Aug-31-23 10:12PM	11 Cheap Small-Cap Stocks to Buy Before the Next Breakout (Insider Monkey)
10:33AM	3 Biotech Stocks Due for a Massive Short Squeeze (InvestorPlace)
08:00AM	Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report (GlobeNewswire)
Aug-29-23 08:00AM	Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3% (GlobeNewswire) +8.98%
Aug-18-23 04:30PM	Arcutis Appoints Interim Chief Financial Officer (CFO) (GlobeNewswire)
Aug-13-23 08:08AM	Broker Revenue Forecasts For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher (Simply Wall St.)
Aug-11-23 06:02AM	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported, And Analysts Assigned A US$41.57 Price Target (Simply Wall St.)
Aug-10-23 08:16AM	Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia (GlobeNewswire)
Aug-09-23 09:23AM	Q2 2023 Arcutis Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:11AM	The past three years for Arcutis Biotherapeutics (NASDAQ:ARQT) investors has not been profitable (Simply Wall St.)
Aug-08-23 06:15PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-23 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-24-23 04:00PM	Arcutis to Report Second Quarter Financial Results (GlobeNewswire)
Jul-17-23 08:00AM	Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark (GlobeNewswire) +16.31%
Jul-05-23 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.17%
Jun-09-23 05:33PM	Why Shares of Arcutis Biotherapeutics Jumped This Week (Motley Fool)
Jun-06-23 04:00PM	Arcutis to Present at Upcoming Investor Conference (GlobeNewswire)
Jun-05-23 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-24-23 05:00PM	Arcutis Announces Leadership Transition (GlobeNewswire) -5.07%
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace) -5.59%
May-09-23 05:45PM	Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:02PM	Arcutis Announces First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
May-05-23 04:00PM	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 08:00AM	Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 (GlobeNewswire)
Apr-28-23 04:01PM	Arcutis Announces Canadian Approval of ZORYVE (roflumilast) Cream 0.3% for Treatment of Plaque Psoriasis in Individuals 12 Years and Older (GlobeNewswire)
Apr-25-23 04:00PM	Arcutis to Report First Quarter Financial Results (GlobeNewswire)
Apr-18-23 08:00AM	Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older (GlobeNewswire)

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its pipeline consists of topical treatments for plaque psoriasis, atopic dermatitis, hand eczema, vitiligo, scalp psoriasis, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne in June 2016 and is headquartered in Westlake Village, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Heron Patrick J	Director	Mar 04 '24	Buy	9.50	21,052	199,994	8,785,284	Mar 06 04:28 PM
Watanabe Todd Franklin	See Remarks	Mar 04 '24	Sale	11.12	14,903	165,739	874,533	Mar 06 05:09 PM
Burnett Patrick	See Remarks	Mar 04 '24	Sale	11.12	4,782	53,182	269,300	Mar 06 05:12 PM
Matsuda Masaru	See Remark	Mar 04 '24	Sale	11.12	3,760	41,816	190,424	Mar 06 05:14 PM
Moore Matthew Richard	SVP and Chief Business Officer	Mar 04 '24	Sale	11.12	3,468	38,568	146,020	Mar 06 05:08 PM
Watanabe Todd Franklin	See Remarks	Feb 28 '24	Sale	10.60	2,465	26,129	889,436	Mar 01 04:11 PM
Burnett Patrick	See Remarks	Jan 02 '24	Sale	3.54	1,325	4,692	57,032	Jan 03 05:30 PM
Watanabe Todd Franklin	See Remarks	Dec 01 '23	Option Exercise	1.68	59,525	100,038	513,682	Dec 01 08:51 PM
Matsuda Masaru	See Remark	Nov 21 '23	Sale	1.98	1,850	3,661	46,634	Nov 21 05:47 PM
Frazier Life Sciences VIII, L.	10% Owner	Oct 24 '23	Buy	2.50	80,000	200,000	8,764,232	Oct 26 04:09 PM
Burnett Patrick	See Remarks	Aug 21 '23	Sale	7.04	1,605	11,302	58,357	Aug 22 12:24 PM
Watanabe Todd Franklin	See Remarks	May 31 '23	Buy	6.38	1,463	9,334	515,145	Dec 01 08:51 PM
Matsuda Masaru	See Remark	May 31 '23	Sale	7.80	1,830	14,278	42,146	Jun 02 08:31 PM

Open in Screener

MIRM

Mirum Pharmaceuticals Inc

Apr 29 • 04:00PM ET

25.07

Dollar change +0.61
Percentage change 2.49	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MIRM Mirum Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWO LABU SCHA VHT VTWO SURI

Index	RUT	P/E	-	EPS (ttm)	-4.03	Insider Own	21.46%	Shs Outstand	46.72M	Perf Week	3.72%
Market Cap	1.18B	Forward P/E	67.23	EPS next Y	0.37	Insider Trans	-0.30%	Shs Float	37.00M	Perf Month	-0.20%
Income	-160.91M	PEG	-	EPS next Q	-0.42	Inst Own	90.88%	Short Float	23.18%	Perf Quarter	-7.56%
Sales	186.37M	P/S	6.34	EPS this Y	70.84%	Inst Trans	11.41%	Short Ratio	17.25	Perf Half Y	-8.97%
Book/sh	5.32	P/B	4.71	EPS next Y	132.46%	ROA	-32.20%	Short Interest	8.58M	Perf Year	-3.39%
Cash/sh	6.08	P/C	4.13	EPS next 5Y	-	ROE	-82.37%	52W Range	23.14 - 35.56	Perf YTD	-15.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.57%	ROI	-28.95%	52W High	-29.50%	Beta	1.14
Dividend TTM	-	Quick Ratio	4.19	Sales past 5Y	88.90%	Gross Margin	75.98%	52W Low	8.34%	ATR (14)	0.98
Dividend Ex-Date	-	Current Ratio	4.45	EPS Y/Y TTM	-0.28%	Oper. Margin	-57.22%	RSI (14)	49.61	Volatility	4.08% 3.61%
Employees	264	Debt/Eq	1.24	Sales Y/Y TTM	141.85%	Profit Margin	-86.33%	Recom	1.10	Target Price	50.50
Option/Short	Yes / Yes	LT Debt/Eq	1.23	EPS Q/Q	28.44%	Payout	-	Rel Volume	0.74	Prev Close	24.46
Sales Surprise	2.49%	EPS Surprise	-162.39%	Sales Q/Q	149.24%	Earnings	Feb 28 AMC	Avg Volume	497.19K	Price	25.07
SMA20	1.12%	SMA50	-5.40%	SMA200	-10.80%	Trades		Volume	369,245	Change	2.49%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-24	Initiated	Stifel	Buy	$48
Dec-18-23	Reiterated	H.C. Wainwright	Buy	$60 → $58
Nov-20-23	Resumed	JP Morgan	Overweight	$37
Nov-13-23	Initiated	Morgan Stanley	Overweight	$60
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Oct-17-23	Resumed	Evercore ISI	Outperform	$62
Sep-20-23	Initiated	JMP Securities	Mkt Outperform	$70
Sep-01-22	Initiated	Citigroup	Buy	$38
Sep-20-21	Initiated	JP Morgan	Overweight	$30
Aug-07-20	Upgrade	Raymond James	Outperform → Strong Buy	$28 → $48
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52
Jul-31-20	Initiated	Piper Sandler	Overweight	$77
Jun-25-20	Initiated	Robert W. Baird	Outperform	$30
Aug-12-19	Initiated	ROTH Capital	Buy	$33
Aug-12-19	Initiated	Raymond James	Outperform	$28
Aug-12-19	Initiated	Guggenheim	Buy	$18
Aug-12-19	Initiated	Evercore ISI	Outperform
Aug-12-19	Initiated	Citigroup	Buy	$21

Show Previous Ratings

Apr-25-24 10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-10-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-02-24 08:30AM	Mirum Pharmaceuticals LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canadas CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome (Business Wire)
Mar-29-24 11:30AM	Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-25-24 11:46PM	Mirum Pharmaceuticals Inc (MIRM) Insider Sells Shares (GuruFocus.com)
07:00AM	Loading…
07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire)
Mar-15-24 09:32AM	Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use (Zacks)
Mar-13-24 06:00PM	Mirum Pharmaceuticals LIVMARLI Receives FDA Approval for Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (Business Wire)
Mar-08-24 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Feb-29-24 11:34AM	Mirum's (MIRM) Q4 Earnings Lag Estimates, Revenues Beat (Zacks)
09:49AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:30AM	Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirums LIVMARLI (Business Wire)
Feb-28-24 05:35PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:38PM	Mirum Pharmaceuticals Inc (MIRM) Reports Robust Revenue Growth and Expanding Commercial ... (GuruFocus.com)
04:03PM	Loading…
04:03PM	Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update (Business Wire)
Feb-21-24 04:05PM	Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call on February 28, 2024 (Business Wire)
Feb-09-24 09:15PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-05-24 07:00AM	NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer (GlobeNewswire)
Jan-23-24 11:44AM	Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback (Zacks)
Jan-19-24 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-16-24 08:30AM	Mirum Pharmaceuticals Appoints Joanne Quan, MD as Chief Medical Officer (Business Wire)
Jan-15-24 04:03AM	Should You Invest in Mirum Pharmaceuticals (MIRM)? (Insider Monkey)
Jan-10-24 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.91%
Jan-08-24 08:30AM	Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates (Business Wire)
Jan-03-24 08:45AM	Mirum Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 01:05PM	United States Steel, NIO rise; Masonite, Mirum Pharmaceuticals fall, Monday, 12/18/2023 (Associated Press Finance) -15.87%
08:37AM	Mirum Pharma's liver disease therapy fails in mid-stage study (Reuters)
08:30AM	Mirum Pharmaceuticals Announces Data from EMBARK Phase 2b Study for Biliary Atresia (Business Wire)
Dec-08-23 07:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:45AM	Loading…
Nov-30-23 09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-20-23 04:05PM	Mirum Pharmaceuticals to Present at the 2023 Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 02:00PM	Mirum Pharmaceuticals Presents New Data at The Liver Meeting (Business Wire) +6.57%
Nov-10-23 05:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-06-23 09:10AM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 UBS Biopharma Conference (Business Wire) +5.67%
Nov-02-23 07:13PM	Mirum Pharmaceuticals Inc (MIRM) Reports Q3 2023 Revenue of $47.7 Million, Up 154% YoY (GuruFocus.com)
04:05PM	Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Oct-30-23 10:00AM	NeoGenomics (NEO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
08:30AM	Mirum Pharmaceuticals to Present New Data at The Liver Meeting (Business Wire)
Oct-27-23 08:45AM	Mirum Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023 (Business Wire)
Oct-17-23 04:30PM	Mirum Pharmaceuticals Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (Business Wire)
Oct-11-23 04:52PM	7 Small-Cap Stocks That Get the Nod from Wall Street (InvestorPlace) -5.79%
Oct-10-23 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-23 05:00PM	Mirum Pharmaceuticals Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN (Business Wire)
Oct-02-23 08:30AM	Mirum Pharmaceuticals Announces Positive Phase 3 RESTORE Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis (Business Wire) -7.28%
Sep-26-23 08:30AM	Mirum Pharmaceuticals to Highlight LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting (Business Wire)
Sep-21-23 08:30AM	Mirum Pharmaceuticals to Present at the 2023 Cantor Global Healthcare Conference (Business Wire)
Sep-15-23 03:05PM	Director Michael Grey Sells 14,608 Shares of Mirum Pharmaceuticals Inc (MIRM) (GuruFocus.com)
08:30AM	Mirum Pharmaceuticals Merits a Healthy Endorsement Based on Its Charts (TheStreet.com)
06:01AM	Strength Seen in Mirum Pharmaceuticals, Inc. (MIRM): Can Its 8.0% Jump Turn into More Strength? (Zacks)
Sep-14-23 01:15PM	Director Patrick Heron Buys 8,437 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com) +8.01%
Sep-13-23 01:01PM	Insider Buying: CFO Eric Bjerkholt Acquires 10,000 Shares of Mirum Pharmaceuticals Inc (GuruFocus.com)
Sep-11-23 10:07AM	Mirum Pharmaceuticals Announces the Appointment of Eric Bjerkholt as Chief Financial Officer (Business Wire)
Sep-08-23 11:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-23 11:19AM	Mirum Pharma (MIRM) Stock Rises 42% Year to Date: Here's Why (Zacks)
08:30AM	Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Sep-05-23 08:30AM	Travere Therapeutics Completes Sale of Bile Acid Product Portfolio to Mirum Pharmaceuticals (GlobeNewswire)
08:30AM	Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Aug-10-23 07:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-03-23 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (Business Wire)
Jul-27-23 04:05PM	Mirum Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023 (Business Wire)
Jul-25-23 05:12PM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks)
08:30AM	Mirums LIVMARLI® Now Authorized in Canada for Cholestatic Pruritus in Patients with Alagille Syndrome (Business Wire)
Jul-20-23 08:18AM	With 67% institutional ownership, Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a favorite amongst the big guns (Simply Wall St.)
Jul-18-23 10:48AM	With $445 million deal, Peninsula company restocks for another run with a late-stage drug (American City Business Journals)
Jul-17-23 02:18PM	Travere Therapeutics Offloads Bile Acid Product Portfolio: Says Divestment Strengthens Financial Foundation (Benzinga)
08:00AM	Travere Therapeutics Enters Agreement to Sell its Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases to Mirum Pharmaceuticals (GlobeNewswire)
08:00AM	Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics (Business Wire)
Jul-10-23 08:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-29-23 09:27AM	Investors push Mirum Pharmaceuticals (NASDAQ:MIRM) 11% lower this week, company's increasing losses might be to blame (Simply Wall St.)
Jun-23-23 12:00PM	Mirum Pharmaceuticals Showcases Five New LIVMARLI (maralixibat) Presentations at the EASL Congress (Business Wire)
Jun-14-23 08:30AM	Event-Free Survival Data from Mirums LIVMARLI Alagille Syndrome Program Published in Hepatology (Business Wire) -5.85%
Jun-09-23 09:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-07-23 08:30AM	Mirum Pharmaceuticals to Present New LIVMARLI Data at the 2023 EASL Congress (Business Wire)
Jun-02-23 08:49AM	There's Reason For Concern Over Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price (Simply Wall St.)
May-19-23 07:00AM	Data from Mirums LIVMARLI Studies Presented at ESPGHAN Annual Meeting (Business Wire)
May-18-23 08:30AM	Hepatology Communications Publishes Data from Mirums LIVMARLI in Primary Sclerosing Cholangitis (Business Wire)
May-17-23 08:30AM	Mirum Pharmaceuticals to Showcase LIVMARLI Data at ESPGHAN Annual Meeting (Business Wire)
May-11-23 08:30AM	Mirum Pharmaceuticals Announces Enrollment Completion in Phase 2b EMBARK Biliary Atresia Study (Business Wire)
May-10-23 09:00PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 02:59PM	Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-06-23 08:05AM	Mirum Pharmaceuticals First Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
May-04-23 06:05PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:02PM	Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (Business Wire)
May-01-23 10:00AM	VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-27-23 04:02PM	Mirum Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 4, 2023 (Business Wire)
10:02AM	Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-25-23 05:44AM	Strength Seen in IDEAYA Biosciences, Inc. (IDYA): Can Its 35.7% Jump Turn into More Strength? (Zacks)
Apr-18-23 06:15AM	Industry Analysts Just Made A Meaningful Upgrade To Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Revenue Forecasts (Simply Wall St.)
Apr-13-23 12:15AM	Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering (Business Wire) +5.44%
Apr-12-23 07:00AM	Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering (Business Wire) -5.92%
06:59AM	Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results (Business Wire)
Apr-10-23 08:30PM	Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-06-23 08:30AM	Industry Leader Tim Walbert Joins Mirum Pharmaceuticals Board of Directors (Business Wire)
Apr-05-23 08:30AM	Mirum Submits for European Approval of LIVMARLI in Progressive Familial Intrahepatic Cholestasis (Business Wire)
Apr-02-23 11:36AM	Top Growth Stocks for April 2023 (Investopedia)
Mar-31-23 06:39AM	Market Sentiment Around Loss-Making Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) (Simply Wall St.) +5.44%
Mar-15-23 09:05AM	Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up (Zacks)

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 27 '24	Buy	24.80	2,000	49,600	14,000	Mar 27 08:47 PM
Radovich Peter	PRESIDENT AND COO	Mar 25 '24	Sale	25.80	4,303	111,017	29,013	Mar 25 05:41 PM
BJERKHOLT ERIC	CHIEF FINANCIAL OFFICER	Mar 18 '24	Buy	25.80	2,000	51,600	12,000	Mar 18 05:34 PM
Peetz Christopher	CHIEF EXECUTIVE OFFICER	Feb 02 '24	Sale	26.19	6,013	157,491	104,112	Feb 05 09:04 PM
Radovich Peter	PRESIDENT AND COO	Feb 02 '24	Sale	26.19	1,790	46,883	34,695	Feb 05 09:05 PM
Vig Pamela	CHIEF SCIENTIFIC OFFICER	Feb 02 '24	Sale	26.19	1,214	31,797	28,691	Feb 05 09:12 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Feb 02 '24	Sale	26.19	847	22,184	104,407	Feb 05 09:10 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Feb 02 '24	Sale	26.19	735	19,251	1,759	Feb 02 09:28 PM
Peetz Christopher	PRESIDENT AND CEO	Jan 08 '24	Sale	28.03	5,209	146,033	110,125	Jan 09 08:12 PM
Radovich Peter	CHIEF OPERATING OFFICER	Jan 08 '24	Sale	28.03	1,408	39,473	36,485	Jan 09 08:28 PM
Vig Pamela	HEAD OF RESEARCH & DEVELOPMENT	Jan 08 '24	Sale	28.03	1,408	39,472	29,905	Jan 09 08:21 PM
Longpre Lara	CHIEF DEVELOPMENT OFFICER	Jan 08 '24	Sale	28.04	1,019	28,568	105,254	Jan 09 08:25 PM
Howe Jolanda	SVP, GLOBAL CONTROLLER	Jan 08 '24	Sale	28.04	528	14,803	722	Jan 09 08:09 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Option Exercise	2.94	2,500	7,350	2,500	Dec 06 05:16 PM
Howe Jolanda	SVP, Global Controller	Dec 05 '23	Sale	32.40	2,500	81,000	0	Dec 06 05:16 PM
GREY MICHAEL G	Director	Sep 14 '23	Option Exercise	2.94	14,216	41,738	14,216	Sep 14 07:33 PM
GREY MICHAEL G	Director	Sep 14 '23	Sale	32.00	14,216	454,912	0	Sep 14 07:33 PM
GREY MICHAEL G	Director	Sep 13 '23	Option Exercise	2.94	392	1,151	392	Sep 14 07:33 PM
Heron Patrick J	Director	Sep 13 '23	Buy	31.02	2,625	81,425	159,053	Sep 15 04:56 PM
GREY MICHAEL G	Director	Sep 13 '23	Sale	32.00	392	12,544	0	Sep 14 07:33 PM
Heron Patrick J	Director	Sep 12 '23	Buy	30.60	3,750	114,764	156,428	Sep 13 04:39 PM
BJERKHOLT ERIC	Chief Financial Officer	Sep 11 '23	Buy	29.65	10,000	296,492	10,000	Sep 12 06:23 PM
Heron Patrick J	Director	Sep 11 '23	Buy	30.30	4,687	142,027	152,678	Sep 13 04:39 PM
Heron Patrick J	Director	Aug 31 '23	Buy	26.25	147,991	3,884,764	147,991	Sep 05 12:51 PM
Howe Jolanda	SVP, Global Controller	Aug 25 '23	Sale	26.23	3,459	90,743	0	Aug 28 04:30 PM
Peetz Christopher	President and CEO	Jul 03 '23	Sale	25.65	5,498	141,005	115,334	Jul 05 07:30 PM
Radovich Peter	Chief Operating Officer	Jul 03 '23	Sale	25.65	1,425	36,546	37,675	Jul 05 07:47 PM
Vig Pamela	Head of Research & Development	Jul 03 '23	Sale	25.65	1,425	36,546	30,786	Jul 05 07:35 PM
Longpre Lara	Chief Development Officer	Jul 03 '23	Sale	25.65	1,004	25,749	105,839	Jul 05 07:37 PM
Howe Jolanda	SVP, Global Controller	Jul 03 '23	Sale	25.65	915	23,467	3,459	Jul 05 07:33 PM
GREY MICHAEL G	Director	Jun 08 '23	Option Exercise	2.94	14,608	42,889	14,608	Jun 09 04:20 PM
GREY MICHAEL G	Director	Jun 08 '23	Sale	29.00	14,608	423,632	0	Jun 09 04:20 PM
GREY MICHAEL G	Director	May 03 '23	Option Exercise	2.94	14,608	42,889	14,608	May 04 09:58 PM
GREY MICHAEL G	Director	May 03 '23	Sale	28.00	14,608	409,024	0	May 04 09:58 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

ARQT

Arcutis Biotherapeutics Inc

MIRM

Mirum Pharmaceuticals Inc

Upgrade your FINVIZ experience